Oral Abstract Session
Glomerular Diseases: Clinical Advances
October 26, 2024 | 04:30 PM - 06:00 PM
Location: Room 6D, Convention Center
Session Description
Oral Abstract Session
Learning Pathway(s)
- Glomerular Diseases
Moderators
Presentations
- Ravulizumab in Atypical Hemolytic Uremic Syndrome: Final Analysis of Efficacy and Safety Outcomes in Two Phase 3 Trials
04:30 PM - 04:40 PM
- Serial Measures of Urine Soluble CD163 Predict Kidney Failure in ANCA-Associated Glomerulonephritis
04:40 PM - 04:50 PM
- Efficacy and Safety of Iptacopan in Patients with C3 Glomerulopathy: 12-Month Results from the Phase 3 APPEAR-C3G Study
04:50 PM - 05:00 PM
- Avacopan beyond the 52-Week Treatment Course
05:00 PM - 05:10 PM
- Noninvasive Assessment of the Presence or Absence of Histologic Activity in Kidney Biopsies from Patients with Lupus Nephritis
05:10 PM - 05:20 PM
- PRRC2A rs114580964 Variant as an Independent Predictor of Poor Kidney Prognosis in Chinese Patients with Lupus Nephritis
05:20 PM - 05:30 PM
- Dispelling the Myth of Sex Differences in Lupus Nephritis (LN): A Pooled Analysis of 779 Patients
05:30 PM - 05:40 PM
- Increased Risk of Cancer in Glomerular Diseases: A Population-Level Analysis
05:40 PM - 05:50 PM
- Major Adverse Cardiovascular Events (MACE) in Proteinuric Glomerulopathies: A CureGN and NEPTUNE Study
05:50 PM - 06:00 PM